Skip to main content
Fig. 5 | BMC Neurology

Fig. 5

From: Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

Fig. 5

Mean (median) annualized percentage brain volume change (PBVC). Results from the SELECT placebo group have been published previously [3]. The annualized PBVC was determined with Structural Image Evaluation using Normalization of Atrophy (SIENA) and was calculated as percentage change divided by the number of days since the last scan multiplied by 365.25. For PBVC endpoints, patients with any post-baseline magnetic resonance imaging assessment in the efficacy population were included in the analysis. *Gold et al. [3]

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us